KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Other Accumulated Expenses (2016 - 2026)

West Pharmaceutical Services has reported Other Accumulated Expenses over the past 18 years, most recently at $202.2 million for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 8.48% to $202.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $202.2 million through Mar 2026, up 8.48% year-over-year, with the annual reading at $175.3 million for FY2025, 6.85% down from the prior year.
  • Other Accumulated Expenses was $202.2 million for Q1 2026 at West Pharmaceutical Services, up from $175.3 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $222.8 million in Q2 2025 and troughed at $2.3 million in Q3 2022.
  • The 5-year median for Other Accumulated Expenses is $169.0 million (2024), against an average of $156.4 million.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 97.98% in 2022 and later skyrocketed 6695.83% in 2023.
  • Tracing WST's Other Accumulated Expenses over 5 years: stood at $183.8 million in 2022, then decreased by 15.56% to $155.2 million in 2023, then grew by 21.26% to $188.2 million in 2024, then decreased by 6.85% to $175.3 million in 2025, then increased by 15.35% to $202.2 million in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $202.2 million, $175.3 million, and $213.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.